This study also revealed that CD24 downregulation by siRNA sensitises HER2-positive breast cancer cells to lapatinib, a HER2-targeted therapy, supporting the idea that targeting CD24 in combination with HER2-targeted therapy might enhance the efficacy of HER2-targeted agents. This evidence concerns the gene ERBB2 and breast carcinoma.